Alexey V. Danilov, MD, PhD

Articles

Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

May 31st 2023

Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.

Overview of Mantle Cell Lymphoma

May 31st 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, provide an overview of mantle cell lymphoma, including prevalence and common risk factors.

BTK Degraders and Other Targets in Mantle Cell Lymphoma

February 28th 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

The Role of Bispecific Antibodies in Mantle Cell Lymphoma

February 21st 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Treating Patients With MCL Who Progress on BTK Inhibitors

February 21st 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

CAR T-Cell Therapy in Patients With MCL: Clinical Trial and Real-World Data

February 14th 2023

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Patient Profile 2: A 60-Year-Old Man With Mantle Cell Lymphoma

February 14th 2023

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

Approaches to Treating Patients With High-Risk Mantle Cell Lymphoma

February 7th 2023

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

Selecting the Appropriate BTKi in MCL and Potential Role of Pirtobrutinib

February 7th 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

BTK Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

January 31st 2023

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

SHINE Study: Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With MCL

January 31st 2023

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?

January 24th 2023

Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.

TRIANGLE Study: Ibrutinib vs Stem Cell Transplant in Younger Patients With MCL

January 24th 2023

Boyu Hu, MD, and Bijal D. Shah, MD, provide their thoughts on the TRIANGLE study looking at ibrutinib versus stem cell transplant in MCL.

Patient Profile 1: A 74-Year-Old Man Diagnosed With Mantle Cell Lymphoma

January 17th 2023

A patient profile of a 74-year-old man diagnosed with mantle cell lymphoma who receives treatment with a non-covalent BTK inhibitor is presented by Alexey V. Danilov, MD, PhD.

Overview of Mantle Cell Lymphoma and First-Line Treatment Options

January 17th 2023

Alexey V. Danilov, MD, PhD, provides an overview of the pathophysiology, symptoms, and subtypes of mantle cell lymphoma.

Dr. Danilov on the Differences Between Covalent and Noncovalent BTK Inhibitors in MCL

October 7th 2022

Alexey V. Danilov, MD, PhD, discusses the key differences between covalent and noncovalent BTK inhibitors in mantle cell lymphoma.

Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLL

September 15th 2022

Looking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.

Pirtobrutinib and Other Non-Covalent BTK Inhibitors in the Treatment of CLL

September 15th 2022

The assembled faculty comment on data on the role of non-covalent BTK inhibitors in the CLL treatment landscape, with emphasis on the phase 1/2 BRUIN trial of pirtobrutinib.

Anti-CD20 Regimens and Triplet Therapies in CLL

September 9th 2022

Orienting the conversation around anti-CD20-drug-based combination and sequencing approaches, the panelists examine key takeaways from the CLL13 and CLL14 clinical trials as well as expectations for real-world data in the future.

Considerations for COVID-19 in MCL and CLL

September 9th 2022

Focusing the discussion on the current state of the COVID-19 pandemic, Catherine C. Coombs, MD, shares key insights into the use of COVID-19 pre-exposure prevention for patients with CLL or MCL.